Novartis' PNH drug succeeds in PhIII and will go to FDA, setting up battle with AstraZeneca
Novartis on Wednesday shared more details from its successful late-stage trial of iptacopan, its drug for the rare blood disease PNH, that it hopes will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
